Xiaomei Liao

Statistics

Publications

Citations

1.8K

H-Index

Active since

2010

Affiliations

Harvard University(Current)

AbbVie (United States)

Brigham and Women's Hospital

AbbVie (Germany)

Western University

Xiaomei Liao is an author at Harvard University specializing in crohn disease pharmacotherapy, epidemiologic methods, and inflammatory bowel disease therapy.

Publications per year

2010–2025

Publications

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 387 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +9

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 316 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +11

The association of long-term exposure to PM2.5 on all-cause mortality in the Nurses’ Health Study and the impact of measurement-error correction

Jaime E. Hart, Xiaomei Liao, Biling Hong et al. · Environmental Health · 2015 · 132 citations · Full text

Public Health, Environmental Sciences, Environmental Health +16

Low-carbohydrate diet scores and risk of type 2 diabetes in men

Lawrence de Koning, Teresa T. Fung, Xiaomei Liao et al. · American Journal of Clinical Nutrition · 2011 · 128 citations · Full text

Medicine, Endocrinology, Nutritional Sciences +14

Plasma carotenoids and risk of breast cancer over 20 y of follow-up

A. Heather Eliassen, Xiaomei Liao, Bernard Rosner et al. · American Journal of Clinical Nutrition · 2015 · 116 citations · Full text

Medicine, Nutritional Sciences, Oncology +14

1–5 of 21